South Korean Samsung Group’s biopharmaceutical business is being reorganized into two separate tracks: contract development ...

SEOUL ― South Korean drugmaker Samsung BioLogics said on Thursday it plans to separate the company into contract manufacturing and development companies to help allay customer concerns about conflicts ...

Seoul: Samsung Biologics, a biotech arm of South Korea's Samsung Group, said on Thursday it plans to spin off its biosimilar ...

In a bid to allay conflict-of-interest concerns, Korean manufacturing giant Samsung Biologics is decoupling from its ...

Pfizer is paying $1.25 billion to join the PD-(L1)xVEGF bispecific race. | Pfizer is paying $1.25 billion to join the ...

Samsung Biologics announced on the 22nd that it will establish 'Samsung Bioepis Holdings' through a simple spin-off method. The plan is to completely separate the contract development and ...

Samsung Biologics Co., the biotech arm of South Korea's Samsung Group, announced Thursday that it plans to spin off its ...

三星生物制剂现在的股价报1,027,000.00 三星生物制剂的股票在哪间交易所挂牌交易？ 三星生物制剂的股票在首尔证券交易所挂牌交易。 三星生物制剂的股票代码是什么？ 三星生物制剂的股票代码是“207940。” 三星生物制剂的市值是多少？ 截至今天，三星生物 ...

SEOUL, May 23 (Yonhap) -- The following are the top headlines in major South Korean newspapers on May 23.

said Thursday it has spun off Daum, the country's second-largest internet portal, in a bid to revive the platform's competitiveness amid a declining market share. During a board of directors meeting, ...